Flag of the European Union EU Clinical Trials Register Help

Clinical trials for nivolumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44043   clinical trials with a EudraCT protocol, of which   7319   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    435 result(s) found for: nivolumab. Displaying page 1 of 22.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2019-003310-14 Sponsor Protocol Number: SHO20190708 Start Date*: 2019-12-05
    Sponsor Name:Department of Dermatology, Bispebjerg Hospital
    Full Title: Laser immunotherapy with and without topical anti-PD1 in basal cell carcinomas
    Medical condition: Basal cell carcinoma in 24-30 patients
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-001707-32 Sponsor Protocol Number: NIVOPTIMIZE-trial Start Date*: 2021-07-08
    Sponsor Name:Erasmus Medical Center Rotterdam
    Full Title: Nivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial)
    Medical condition: Patients with advanced or metastatic melanoma or renal cell carcinoma treated with nivolumab monotherapy in a 480mg or 6 mg/kg 4 weekly scheme (either from start or after combination therapy with i...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001641-13 Sponsor Protocol Number: CA224-098 Start Date*: 2022-01-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab +Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
    Medical condition: participants with completely resected Stage III or Stage IV melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) BE (Ongoing) FR (Trial now transitioned) CZ (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) NO (Trial now transitioned) FI (Trial now transitioned) ES (Ongoing) IT (Ongoing) GR (Trial now transitioned) PT (Completed) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2021-003208-42 Sponsor Protocol Number: CA209-6GE Start Date*: 2022-06-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Open Label, Randomized, Non-Inferiority Pharmacokinetic Study of Nivolumab Administered Subcutaneously (Nivo SC) Versus Intravenous Administration of Nivolumab in Participants with Stage...
    Medical condition: Resected Stage IIIA/B/C/D or Stage IV melanoma in an adjuvant setting
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) BE (Completed) PL (Completed) DE (Prematurely Ended) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004760-11 Sponsor Protocol Number: CA209-408 Start Date*: 2016-08-25
    Sponsor Name:VU Medical Centre
    Full Title: 89Zirconium-labeled nivolumab and 18F-labeled anti-PD-L1 as predictive imaging biomarkers of response and toxicity in nivolumab treated patients with non-small-cell lung cancer – a feasibility study
    Medical condition: Non-small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002499-14 Sponsor Protocol Number: CA017-055 Start Date*: 2018-03-01
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined with Nivolumab versus Nivolumab in Participants with Metastatic or Unresectable Melanoma that is Previously Untreated
    Medical condition: Metastatic or Unresectable Melanoma that is Previously Untreated
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Completed) GB (Completed) IE (Completed) CZ (Completed) GR (Completed) PL (Completed) FR (Completed) Outside EU/EEA IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004816-39 Sponsor Protocol Number: CA012-004 Start Date*: 2016-08-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination with Nivolumab or Ipilimumab in Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002469-37 Sponsor Protocol Number: CA209-7FL Start Date*: 2020-01-29
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With Hi...
    Medical condition: Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061020 Breast cancer male PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) CZ (Completed) FR (Completed) PL (Completed) NL (Completed) BE (Completed) DK (Completed) FI (Completed) IE (Completed) ES (Ongoing) PT (Completed) GB (GB - no longer in EU/EEA) IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002441-61 Sponsor Protocol Number: CA209-451 Start Date*: 2016-01-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell ...
    Medical condition: Extensive stage disease small cell lung cancer who have completed first line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) GR (Completed) SE (Completed) DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) IE (Completed) FI (Completed) PL (Completed) NL (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-003108-10 Sponsor Protocol Number: GOING Start Date*: 2020-01-14
    Sponsor Name:Fundació Clinic per a la Recerca Biomèdica
    Full Title: The GOING Study: Regorafenib followed by Nivolumab in patients with Hepatocellular Carcinoma progressing under sorafenib
    Medical condition: Hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002939-21 Sponsor Protocol Number: AARON Start Date*: 2020-06-15
    Sponsor Name:Klinikum der Universität München
    Full Title: An Open-Label Phase II Study of Relatlimab (BMS-986016) with Nivolumab (BMS- 936558) in Combination with 5-Azacytidine for the Treatment of Patients with Refractory/Relapsed Acute Myeloid Leukemia ...
    Medical condition: Subjects with Acute myeloid leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001941 AML LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001150-35 Sponsor Protocol Number: AxIn Start Date*: 2022-11-10
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: Phase II study of axitinib intensification plus nivolumab compared to nivolumab alone after induction with nivolumab plus ipilimumab in mRCC patients without previous complete response (AxIn study).
    Medical condition: Metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003655-15 Sponsor Protocol Number: CA209-67T Start Date*: 2021-06-02
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Open-label, Randomized, Noninferiority Trial of Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carci...
    Medical condition: Metastatic Clear Cell Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10050076 Metastatic renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) PL (Trial now transitioned) CZ (Ongoing) PT (Trial now transitioned) FI (Trial now transitioned) IT (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003583-12 Sponsor Protocol Number: CA224-047 Start Date*: 2018-05-30
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma
    Medical condition: Previously Untreated Metastatic or Unresectable Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) GR (Trial now transitioned) FI (Trial now transitioned) PL (Trial now transitioned) Outside EU/EEA IT (Ongoing) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004914-79 Sponsor Protocol Number: CA017-003 Start Date*: 2016-10-22
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors
    Medical condition: Advanced Malignant Tumors
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Completed) NO (Completed) FI (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001018-76 Sponsor Protocol Number: CA209-649 Start Date*: 2016-10-10
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Ga...
    Medical condition: Gastric or Gastroesophageal Junction Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) GR (Ongoing) PL (Completed) HU (Completed) DE (Completed) PT (Completed) FR (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002673-28 Sponsor Protocol Number: NL82177.078.22 Start Date*: 2023-01-31
    Sponsor Name:Erasmus MC
    Full Title: Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with fi...
    Medical condition: Stage III irresectable or metastatic melanoma treated with first-line ipilimumab-nivolumab
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002676-40 Sponsor Protocol Number: CA045-009 Start Date*: 2019-07-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR-214), Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Can...
    Medical condition: Muscle-Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) AT (Completed) GR (Completed) ES (Ongoing) CZ (Completed) PL (Completed) FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-002544-32 Sponsor Protocol Number: UCL/15/0515 Start Date*: 2018-03-01
    Sponsor Name:University College London
    Full Title: A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first ...
    Medical condition: Relapsed/refractory Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020266 Hodgkin's disease recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020267 Hodgkin's disease refractory PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-000603-91 Sponsor Protocol Number: CA013-004 Start Date*: 2016-08-30
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2a Study of BMS-986179 Administered in Combination with Nivolumab (BMS- 936558) in Subjects with Advanced Solid Tumors
    Medical condition: Solid tumors
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA